MK-7264, a P2X3 receptor antagonist, reduces cough frequency in patients with refractory chronic cough: Results from a randomized, controlled, Phase 2b clinical trial

Tuesday, January 25th, 2022

This was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, efficacy and therapeutic dose range of MK-7264 for the treatment of chronic cough; overall, 253 patients from the United States and the United Kingdom were included in the study. Cough frequency was measured using the Vitalograph VitaloJAK device.